.jpg?format=webp&quality=80&width=3840)
A study involving 84,440 premature infants born before 32 weeks gestational age has examined the timing of postnatal dexamethasone (PND) treatment. The study found that commencing PND after 5 weeks of age was associated with worse respiratory outcomes, including increased mortality and severe bronchopulmonary dysplasia (BPD). Infants receiving PND at this stage had delayed extubation and potentially required respiratory support at discharge.
Like
Save
Share